Discussions on with Indian govt for expedited approval of COVID-19 vaccine, says Pfizer
CEO Albert Bourla said that Pfizer is aware that 'access to vaccines is critical'. 'Unfortunately, our vaccine is not registered in India although our application was submitted months ago,' the CEO added
Global Pharma major Pfizer is discussing with the Indian government an expedited approval pathway to make Pfizer-BioNTech vaccine available for use in the country, the company’s Chairman and CEO Albert Bourla said on Monday.
Earlier in April, Pfizer said that it had offered a not-for-profit price for its vaccine for the government immunisation programme in India and it remains committed to continuing engagement with the government to make the vaccine available in India.
“Pfizer is aware that access to vaccines is critical to ending this pandemic. Unfortunately, our vaccine is not registered in India although our application was submitted months ago. We are currently discussing with the Indian government an expedited approval pathway to make our Pfizer-BioNTech vaccine available for use in the country,” Bourla said in a mail sent to Pfizer India employees that he has shared on his LinkedIn post.
Pfizer has earlier said that, during the pandemic phase, it will supply the Pfizer-BioNTech COVID-19 mRNA vaccine only through government contracts.
“Pfizer remains committed to continuing our engagement with the government towards making the Pfizer and BioNTech vaccine available for use in the government’s immunisation programme in the country,” the company had said in April in an email response to PTI.
The Indian government last month allowed emergency use approval of the imported vaccines in India which have been granted emergency approval for restricted use by the United States Food and Drug Administration (USFDA), European Medicines Agency (EMA), UK Medicines and Healthcare products Regulatory Agency (UK MHRA), Pharmaceuticals and Medical Device Agency (PMDA) Japan or which are listed in WHO (emergency use listing).
Moderna and Johnson & Johnson are also conducting trials of its vaccine in teens and younger children as well.
BioNTech CEO Ugur Sahin said ongoing trials are "very encouraging" and that "children are very well protected by the vaccine".
COVID-19 vaccination: Delays in inoculating 18-44 could severely disrupt efforts to control second wave
While all people above 18 years of age are now eligible to receive coronavirus vaccines, the key question is when adequate jabs will be available